-+ 0.00%
-+ 0.00%
-+ 0.00%

Shaanxi Micot Says All Participants Complete MT1013 Phase III Trial Treatment and Follow-Up

PUBT·11/09/2026 04:07:05
Listen to the news
Shaanxi Micot Says All Participants Complete MT1013 Phase III Trial Treatment and Follow-Up
  • Shaanxi Micot announced Nov. 9, 2026, that all participants completed treatment and follow-up in its Phase III MT1013 trial.
  • The 435-patient study compared MT1013 with cinacalcet for chronic kidney disease-related secondary hyperparathyroidism in patients receiving maintenance hemodialysis.
  • Available monitoring data identified no new major safety signals; participant discontinuations were broadly in line with expectations.
  • The trial remains blinded, with final analysis pending; safety and efficacy results will be presented in the final clinical study report.
  • Subject to supportive results, the company plans to submit a new drug application to China's National Medical Products Administration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaanxi Micot Pharmaceutical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12405141), on November 09, 2026, and is solely responsible for the information contained therein.